Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC. Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clin Cancer Res. 2023 Nov 22. doi: 10.1158/1078-0432.CCR-23-0163. Online ahead of print. PMID: 37992313
Jungius S, Grosheintz K, Adam FC, Medinger M, Buser AS, Passweg JR, Halter JP, Meyer SC. Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Front Oncol. 2023 Aug 10;13:1205387. doi: 10.3389/fonc.2023.1205387. eCollection 2023. PMID: 376370
Konantz M, Williams M, Merkel T, Reiss A, Dirnhofer S, Meyer SC, Valent P, George TI, Tzankov A, Hartmann K. Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis. J Allergy Clin Immunol. 2023 Oct;152(4):1019-1024. doi: 10.1016/j.jaci.2023.07.001. Epub 2023 Jul 8. PMID: 37423405
Konantz M, Merkel T, Meyer SC, Hartmann K. MRGPRX2, a novel biomarker in mastocytosis? J Allergy Clin Immunol Pract. 2023 Feb;11(2):669-671. PMID 36759088. DOI: https://doi.org/10.1016/j.jaip.2022.
Kirsch M, Stehle GT, Konantz M, Passweg J, Dirnhofer S, Meyer SC, Hartmann K. Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis. J Allergy Clin Immunol Pract. 2022 Jul 22:S2213-2198(22)00714-0. PMID: 35872218. DOI: https://doi.org/10.1016/j.jaip.2022.07.014.
Parmigiani E, Ivanek R, Rolando C, Hafen K, gerber A, Lehmann FM, Brkic S, Frank S, Meyer SC, Wakimoto H, Günel M, Louvi A, Mariani L, Finke D, Holländer G, Hutter G, Tussiwand R, Taylor V, Giachino C. Tumor niche strength underlies interferon-gamma resistance and immune evasion in proneural glioma. Dev Cell. 2022:57(15):1847-1865.e9. PMID: 35803280. DOI:10.1016/jdevcel.2022.06.006.
Kirsch M, Stehle GT, Konantz M, Passweg JR, Dirnhofer S, Meyer SC, Hartmann K. Neoplastic mast cells in ascites in advanced systemic mastocytosis: a valuable marker for diagnosis and treatment response. J Allergy Clin Immunol Pract. 2022:52213-2198(22)00714-0. PMID 35872218. DOI:10.1016/j.jaip.2022.07.014.
Adam FC, Szybinski J, Halter JP, Cantoni N, Wenzel F, Leonards K, Brkic S, Passweg JR, Touw I, Maxson JE, Meyer SC. Co-occurring SF3R W791* germline and somatic T618I driver mutations induce early CNL and clonal progression to mixed phenotype acute leukemia. Currncol. 2022 Feb;29(2):805-815. PMID: 35200567. DOI: https://doi.org/10.3390/curroncol29020068.
Bader MS, Meyer SC. JAK2 in myeloproliferative neoplasms: still a protagonist. Pharmaceuticals. 2022 Jan 28;15(2):160. PMID: 35215273. DOI: https://doi.org/10.3390/ph15020160.
Stivala S, Meyer SC. Recent advances in molecular diagnostics and targeted therapy of myeloproliferative neoplasms. Cancers. 2021 Oct 9;13(20):5035. PMID: 34680185. DOI: https://doi.org/10.3390/cancers13205035.
Brkic S, Stivala S, Santopolo A, Szybinski J, Jungius S, Passweg JR, Tsakiris D, Dirnhofer S, Lischer HE, Dettmer MS, Neel BG, Levine RL, Meyer SC. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia. 2021 Oct;35(10):2875-2884. PMID: 34480104. DOI: https://doi.org/10.1038/s41357-021-01391-2.
Zeeh F, Meyer SC. Current concepts on pathophysiology and treatment of BCR-ABL-negative myeloproliferative neoplasms. Hämostaseologie. 2021 Jun;41(3):197-205. PMID: 34192778. DOI: https://doi.org/10.1055/a-1447-6667.
Person F, Meyer SC, Hopfer H, Menter T. Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Virchows Archiv. 2021 Jun 23. PMID: 34164707. DOI: https://doi.org/10.1007/s00428-021-03129-y.
Szybinski J, Meyer SC. Genetics of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021 Apr;35(2):217-236. PMID: 33641865. DOI: https://doi.org/10.1016/j.hoc.2020.12.002.
Brkic S, Meyer SC. “Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms”. HemaSphere. 2020 Dec 29;5(1):e516. PMID33403355. DOI: https://doi.org /10.1097/HS9.0000000000000516.
Nienhold R, Ashcroft P, Zmajkovic J, Rai S, Rao TN, Drexler B, Meyer SC, Lundberg P, Passweg JR, Lekovic D, Cokic V, Bonhoeffer S, Skoda RC. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 Nov 26; 36(22):2591-2595. PMID: 32698197. DOI: https://10.1182/blood.2019002943.
Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Chiu S, Keller M, Kleppe M, Hilpert M, Buser A, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 Mar4;129(4):1596-1611. PMID: 30730307. DOI: https://doi.org/10.1172/JCI98785.
Meyer SC, Drexler B, Skoda RC. Myeloproliferative neoplasms – Update on diagnosis and treatment. Ther Umsch. 2019;76(9):487-495. PMID: 32157965. DOI: https://10.1024/0040-5930/a001128.
Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell. 2018 Jan 8;33(1):44-59.e8. PMID: 29275866. DOI: https://doi.org/10.1016/j.ccell.2017.11.012.
Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD. Mediator kinase phosphorylation of STAT1 S727 is required for neoplasms with JAK-STAT activation. Ebiomedicine. 2017 Dec 26:112-125. Epub 2017 Nov 21. PMID: 29239838. DOI: https://doi.org/10.1016/j.ebiom.2017.11.013.
Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH. In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Haematologica. 2017 Dec;102(12):e504-e505. PMID: 29192132. DOI: https://doi.org/10.3324/haematol.2017.181818.
Meyer SC. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 Aug;31(4):627-42. Epub 2017 May 13. PMID: 28673392. DOI: https://doi.org/10.1016/j.hoc.2017.04.003.
Meyer SC, Steinmann E, Lehmann T, Muesser P, Passweg JR, Skoda RC, Tsakiris DA. Anti-platelet factor 4/heparin antibody formation occurs endogenously and at unexpected high frequency in polycythemia vera. Biomed Res Int. 2017; 2017:9876819. Epub 2017 Jun 18. PMID: 28698883. DOI: https://doi.org/10.1155/2017/9876819.
Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH. Amotosalen/UVA Pathogen Reduction Technology Induces Platelet Apoptosis and Accelerates Platelet Clearance. Haematologica. 2017 Oct; 02(10)1650-1660. Epub 2017 Jul 20. PMID: 28729303. DOI: https://doi.org/10.3324/haematol.2017.164137.
Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Vannucchi A, Guglielmelli P, Milosevic J, Kralovics R, Dirnhofer S, Orkin SH, Skoda RC. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 Jul 25;213(8):1479-96. Epub 2016 Jul11. PMID: 27401344. DOI: https://doi.org/10.1084/jem.20151136.
Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016 Aug 11;128(6):839-51. Epub 2016 Jun 10. PMID: 27288519. DOI:https://doi.org/10.1182/blood-2015-12-689216.
Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova O, Rapaport F, Ke Xu, Manova K, Pankov D, O’Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Damassa E, Romanet V, Doelemeyer A, Zender M, Heinlein M, Rampal R, Singer R, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28. PMID: 26175413. DOI:https://doi.org/10.1016/j.ccell.2015.06.006.
Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL.Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014 Oct 2;124(14):2280-4. Epub 2014 Aug 12. PMID: 25115888. DOI: https://doi.org/10.1182/blood-2014-03-560441.
O’Meara A, Holbro A, Meyer SC, Martinez M, Medinger M, Buser A, Halter J, Heim D, Gerull S, Bucher C, Rovo A, Kuhne T, Tichelli A, Gratwohl A, Stern M, Passweg JR. Forty years of hematopoietic stem cell transplantation: a review of the Basel experience. Swiss Med Wkly. 2014 Feb 24;144:w13928. PMID: 24567259. DOI: https://doi.org/10.4414/smw.2014.13928Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukemia. Lancet Oncol. 2014 Aug;15(9):e382-94. PMID: 25079101. DOI: https://doi.org/0.1016/S1470-2045(14)70008-7.
Meyer SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014 Apr 15;20(8):2051-9. Epub 2014 Feb 28. PMID: 24583800. DOI: https://doi.org/10.1158/1078-0432.CCR-13-0279.
Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013 Nov 27;5(4):1047-59. Epub 2013 Nov 21. PMID: 24268771. DOI: https://doi.org/10.1016/j.celrep.2013.10.038.
